Reaction

Implant Site Urticaria reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 79 reports · 1 co-occurring drugs

As of the last recalculation, Implant Site Urticaria appears in 79 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL (PRR 1,856.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Etonogestrel641,856.61,859.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.